Loading
FGF3 (Fibroblast growth factor 3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Hepatocellular carcinoma.
Plays an important role in the regulation of embryonic development, cell proliferation, and cell differentiation. Required for normal ear development.
CIViC holds 3 clinical evidence items and 0 assertions across 1 variant, naming Sorafenib and Dovitinib. Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.49, affected pathway 0.92, animal model 0.25, genetic association 0.13).
In plain words · FGF3 (Fibroblast growth factor 3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Hepatocellular carcinoma.
FGF3 (Fibroblast growth factor 3) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and Hepatocellular carcinoma.
Plays an important role in the regulation of embryonic development, cell proliferation, and cell differentiation. Required for normal ear development.
No product in this corpus aims at FGF3 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA FGF3: RNA tissue enriched (brain 5 nTPM); high antibody staining in 1 normal tissue. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Hepatocellular carcinoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas FGF3 tissue; Open Targets ENSG00000186895 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Brooks et al, Oncogene, 1989, "Sequence organization of the human int-2 gene and its expression in teratocarcinoma cells". Source.
Sources: HGNC HGNC:3681 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P11487 (protein name, function text, keywords and locations (REST API)); CIViC gene FGF3 (3 evidence items, 0 assertions, 1 variants; diseases: Breast Cancer, Hepatocellular Carcinoma, Cancer (GraphQL API, CC0)); Open Targets ENSG00000186895 (association with cancer (MONDO_0004992) 0.66; (GraphQL API, CC0))
Plays an important role in the regulation of embryonic development, cell proliferation, and cell differentiation. Required for normal ear development. Location: Secreted (UniProt). Locus 11q13.3 (HGNC).
RNA: tissue enriched (brain 5 nTPM), detected in single normal tissue.
RNA cancer enhanced: Stomach Adenocarcinoma 2 pTPM.
No cancer stained high; medium in breast cancer, cervical cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FGF3" OR ABSTRACT:"FGF3" OR TITLE:"fibroblast growth factor 3" OR ABSTRACT:"fibroblast growth factor 3" OR TITLE:"Fibroblast growth factor 3" OR ABSTRACT:"Fibroblast growth factor 3" OR TITLE:"HBGF-3" OR ABSTRACT:"HBGF-3" OR TITLE:"INT2" OR ABSTRACT:"INT2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FGF3, not a curated reading list.